Clinical trials: Chest--Diseases
Stage III Non-small Cell Lung Cancer
Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)
Radiochemotherapy is a standard for the treatment of unresectable stage III non-small cell lung cancer. The investigators goal is to study the efficacy and the toxicity for a promising association of new agents (cetuximab and…
- Trial name
- NCT01102231
- Testing
- Chemotherapy, ERBITUX, Radiotherapy
- Where
- 38 sites in France
- Volunteers
- 106 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Carcinoma, Non-Small Cell Lung Cancer (NSCLC)
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
The purpose of the study is to determine if nab-paclitaxel and carboplatin chemotherapy plus necitumumab is effective and safe in participants with stage IV squamous non-small cell lung cancer.
- Trial name
- NCT02392507
- Testing
- Necitumumab, Nab-Paclitaxel, Carboplatin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Eli Lilly and Company
Small Cell Lung Cancer
Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer
This study was a Phase I/II trial primarily focused on efficacy of BB-10901 in relapsed small cell lung cancer and other solid tumors.
- Trial name
- NCT00065429
- Testing
- BB-10901
- Where
- 11 sites in United States
- Volunteers
- 64 people
- Sponsor
- ImmunoGen, Inc.
Lung Cancer
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00227539
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Metastatic Lung Cancer
Safety and Efficacy of Cryoablation for Metastatic Lung Tumors
ECLIPSE will evaluate the safety and efficacy of cryoablation therapy used to treat tumors less than or equal to 3.5 centimeters (cm) in participants with pulmonary metastatic disease.
- Trial name
- ECLIPSE (NCT01307501)
- Testing
- Cryoablation
- Where
- 4 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Boston Scientific Corporation
ALK Gene Translocation, EGFR Activating Mutation
Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of plinabulin when given together with nivolumab and to see how well they work in treating patients with stage IIIB-IV non-small cell lung cancer that has come back or…
- Conditions
- ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation
- Trial name
- NCT02846792
- Testing
- Nivolumab, Plinabulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Washington
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
A study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb), in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT01307267
- Testing
- PF-05082566, rituximab
- Where
- 42 sites in United States, Australia and 3 more
- Volunteers
- 190 people
- Sponsor
- Pfizer
Lung Cancer, Precancerous Condition
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Iloprost may be effective in preventing lung cancer.
- Trial name
- NCT00084409
- Testing
- iloprost
- Where
- 6 sites in United States
- Volunteers
- 152 people
- Sponsor
- University of Colorado, Denver
Stage IV Lung Cancer
Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer
Current therapies for Stage IV Lung Cancer provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of Stage IV Pancreatic Cancer.
- Trial name
- NCT00003492
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Burzynski Research Institute
Angina, Unstable, Cardiovascular Diseases
IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.
The purpose of this study is to test the impact of pharmacological myocardial metabolic support, in the form of intravenous (IV) glucose, insulin and potassium (GIK), for the treatment of patients with threatened or established…
- Conditions
- Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease
- Trial name
- IMMEDIATE (NCT00091507)
- Testing
- GIK
- Where
- 13 sites in United States
- Volunteers
- 911 people
- Sponsor
- Tufts Medical Center
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00368992
- Testing
- cetuximab, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small-Cell Lung
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings
This non-interventional study will include a representative sample of patients with locally advanced or metastatic NSCLC harboring Epidermal Growth Factor Receptor (EGFR)-mutations in Greece.
- Trial name
- NCT02440854
- Testing
- afatinib
- Where
- 7 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Non-small Cell Lung Cancer, Cachexia
Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.
The purpose of this study is to assess the frequency of cachexia and the management of cachexia and associated symptoms in a patient population with non-small cell lung cancer (NSCLC).
- Trial name
- CacheMire (NCT02968979)
- Where
- France
- Volunteers
- 539 people
- Sponsor
- Chugai Pharma France
Lung Carcinoma
Risk and Benefits of Electronic Cigarettes to Older Smokers at High Risk for Lung Cancer
This clinical trial investigates the effects of switching from smoking regular cigarettes to electronic cigarettes (e-cigarettes) among older adult smokers at high risk for lung cancer.
- Trial name
- NCT05144542
- Testing
- Nicotine Replacement
- Where
- United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
This phase II trial studies how well Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in treating patients with stage I-IIIA non-small cell lung cancer that can be removed by surgery.
- Conditions
- Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
- Trial name
- NCT03366766
- Testing
- Nivolumab, Cisplatin, Pemetrexed Disodium
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lung Cancer
Digital Outreach Intervention for Lung Cancer Screening
mPATH-Lung (mobile Patient Technology for Health - Lung) is an innovative digital outreach program that identifies patients who qualify for lung cancer screening and helps them get screened.
- Trial name
- mPATH-Lung (NCT04083859)
- Testing
- mPATH-Lung, Lung health video
- Where
- 2 sites in United States
- Volunteers
- 26,998 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Non-small Cell Lung Cancer Stage I
Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
This is a pilot study to compare pre- and post-SABR core biopsies of stage I NSCLC tumors to identify SABR-induced immune-mediated tumor recognition based on a significant and specific expansion of T-cell clones using a novel…
- Trial name
- NCT03603002
- Testing
- Post-SABR Biopsy
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Non-Small Cell Lung Cancer
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study was to see how well three investigational drugs worked together in preventing progression of the disease.
- Trial name
- NCT00356122
- Testing
- Docetaxel, Oxaliplatin, Bevacizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Sanofi
Carcinoma, Non-Small-Cell Lung
Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
This is a phase II, single institution trial for patients with clinical Stage IB-IIIA NSCLC (T1-3N0-2M0) who have resectable lung tumors.
- Trial name
- NCT00130780
- Testing
- Pre-surgical Treatment with Bevacizumab plus Chemotherapy, Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Carcinoma, Non-Small- Cell Lung
A Study of SEA-CD40 Given With Other Drugs in Cancers
This trial is being done to see if an experimental drug (SEA-CD40) works when it's given with other cancer drugs to treat some types of cancer. It will also study side effects from the drug. There are 2 parts in this trial.
- Trial name
- NCT04993677
- Testing
- SEA-CD40, pembrolizumab (KEYTRUDA®), pemetrexed
- Where
- 29 sites in United States, Canada and 4 more
- Volunteers
- 77 people
- Sponsor
- Seagen Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.